% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

  • solantey Oct 21, 2012 10:23 AM Flag

    Mannkind - MNKD - Consider Buying A Few Shares Under $2.00

    The announcement that Mannkind has issued a new secondary to raise funds has created a buying opportunity.

    Mannkind's insulin drug, Afrezza, could receive F.D.A. approval as early as September,2013 if it is granted "priority review" status.

    With $1.6 billion in tax-loss carry forwards and insulin inventory to produce $10,000,000,000 worth of Afrezza the company in a potential takeover target which may be why the company's billionaire C.E.O., Al Mann, converted over $100 million in debt owed to him by the company at $2.59/share last week.

    A "big-pharma" partnership could happen at any time.

    Consider buying a few shares below $2.00 before the approval run-up begins.

45.95+0.89(+1.98%)Oct 25 4:00 PMEDT